Dr. Kamalika Mukherjee earned her Ph.D. in Chemistry from the State University of New York at Binghamton, where she developed innovative chemical biology technologies to address key questions in anti-cancer drug discovery and development. She continued her research in the Nephrology Division at Massachusetts General Hospital and the Department of Medicine at Harvard Medical School, first as a Research Fellow and then as an Instructor. Her work there centered on identifying and validating biomarkers and therapeutic targets, as well as proposing innovative treatment strategies for kidney and metabolic diseases.

Currently, Dr. Mukherjee serves as the Associate Director of Assay Development and Principal Investigator at the Sealy Institute for Drug Discovery (SIDD) at UTMB, where she also leads the SIDD Clinical Laboratory. Her current research focuses on developing diagnostic and therapeutic approaches based on disease-associated biomarkers. Her scientific pursuits are inspired by her passion for translating research insights into clinical solutions that improve patient outcomes.

Dr. Mukherjee is equally passionate about empowering the next generation of scientists to achieve their professional goals.